Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement levels in septic primates treated with anti-C5a antibodies.

D H Hangen1, J H Stevens, P S Satoh

  • 1Division of Respiratory Medicine, Stanford University Medical Center, California 94305.

The Journal of Surgical Research
|March 1, 1989
PubMed
Summary

This study shows that blocking complement anaphylatoxin C5a significantly reduces septic shock and lung injury in primates during gram-negative sepsis. Targeting C5a offers a potential therapeutic strategy for sepsis-induced acute respiratory distress syndrome.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis.

Vaccine·2022
Same author

Medical disease and the anæsthetist.

Proceedings of the Royal Society of Medicine·2010
Same author

Torsion of the Gall-bladder.

British medical journal·2010
Same author

Use of x-rays in obstetrics.

Journal - Michigan State Medical Society·2010
Same author

Ethical consideration of incidental findings on adult brain MRI in research.

Neurology·2004
Same author

Pharmacogenomics and the challenge to privacy.

The pharmacogenomics journal·2002

Area of Science:

  • Immunology
  • Pathophysiology
  • Pharmacology

Background:

  • Gram-negative sepsis involves endotoxin activating the complement system.
  • Complement anaphylatoxin C5a is implicated in neutrophil recruitment and lung injury, potentially causing adult respiratory distress syndrome.
  • Understanding complement's role is crucial for developing sepsis treatments.

Purpose of the Study:

  • To investigate the role of complement anaphylatoxin C5a in neutrophil-mediated lung injury during experimental gram-negative sepsis.
  • To evaluate the efficacy of anti-C5a antibodies in mitigating septic shock and pulmonary edema in a primate model.
  • To analyze complement component levels and activation pathways during sepsis.

Main Methods:

  • Experimental sepsis was induced in primates via Escherichia coli infusion.

Related Experiment Videos

  • Three groups were studied: control, septic, and septic treated with anti-human C5a antibodies.
  • Complement component levels (C3, C4, C5) and anaphylatoxins (C3a, C4a, C5a) were measured using radial immunodiffusion and radioimmunoassay.

    • Main Results:

    • Anti-C5a antibody treatment significantly attenuated septic shock and pulmonary edema.
    • Septic groups showed depletion of C3, C4, and C5 complement levels, indicating both alternate and classical pathway activation.
    • While early C3a and C4a levels were similar, peak C5a levels were 42% lower in the anti-C5a treated group, which did not elevate above control levels post-peak.
    • The anti-human C5a antibody demonstrated cross-reactivity with primate C5a and specificity.

    Conclusions:

    • Complement anaphylatoxin C5a plays a critical role in sepsis-induced lung injury.
    • Neutralization of C5a with specific antibodies can effectively reduce septic shock and pulmonary edema.
    • Targeting C5a represents a promising therapeutic approach for managing severe sepsis and acute respiratory distress syndrome.